Mural Oncology (MURA) Competitors $2.49 +0.02 (+0.81%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$2.48 -0.01 (-0.20%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. CYBN, RAPT, TLSA, ACOG, BDTX, DERM, KYTX, ACRS, BIOA, and IPHAShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Cybin (CYBN), Rapt Therapeutics (RAPT), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Black Diamond Therapeutics (BDTX), Journey Medical (DERM), Kyverna Therapeutics (KYTX), Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Its Competitors Cybin Rapt Therapeutics Tiziana Life Sciences Alpha Cognition Black Diamond Therapeutics Journey Medical Kyverna Therapeutics Aclaris Therapeutics BioAge Labs Innate Pharma Mural Oncology (NASDAQ:MURA) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders believe in MURA or CYBN? 80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 2.2% of Mural Oncology shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is MURA or CYBN more profitable? Cybin's return on equity of -37.58% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -83.39% -70.70% Cybin N/A -37.58%-36.59% Do analysts recommend MURA or CYBN? Mural Oncology currently has a consensus target price of $12.00, indicating a potential upside of 381.93%. Cybin has a consensus target price of $85.00, indicating a potential upside of 904.73%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor MURA or CYBN? In the previous week, Cybin had 2 more articles in the media than Mural Oncology. MarketBeat recorded 2 mentions for Cybin and 0 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 1.89 beat Cybin's score of 0.69 indicating that Mural Oncology is being referred to more favorably in the media. Company Overall Sentiment Mural Oncology Very Positive Cybin Positive Which has more risk & volatility, MURA or CYBN? Mural Oncology has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Which has higher valuation and earnings, MURA or CYBN? Cybin is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$128.51M-$7.67-0.32CybinN/AN/A-$57.88M-$3.88-2.18 SummaryCybin beats Mural Oncology on 10 of the 14 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.65M$2.43B$5.56B$9.34BDividend YieldN/A1.79%3.80%4.06%P/E Ratio-0.329.1828.0519.86Price / SalesN/A725.87437.8999.92Price / CashN/A161.2635.8457.94Price / Book0.304.748.255.67Net Income-$128.51M$30.99M$3.24B$257.80M7 Day Performance2.05%2.49%1.45%1.87%1 Month Performance0.81%10.38%8.04%10.92%1 Year Performance-27.19%-0.55%30.08%18.51% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.4562 of 5 stars$2.49+0.8%$12.00+381.9%-28.4%$42.65MN/A-0.32119Positive NewsCYBNCybin2.8367 of 5 stars$7.38-1.3%$85.00+1,052.5%N/A$171.53MN/A-1.7050RAPTRapt Therapeutics4.3898 of 5 stars$10.30+18.1%$19.80+92.3%-64.8%$171.27M$1.53M-0.5480High Trading VolumeTLSATiziana Life Sciences1.0714 of 5 stars$1.45-2.4%N/A+86.4%$168.85MN/A0.008ACOGAlpha Cognition1.7632 of 5 stars$10.47-0.6%$20.00+91.0%N/A$167.73M$2.93M-8.72N/AGap UpBDTXBlack Diamond Therapeutics2.6984 of 5 stars$2.93-0.5%$12.80+337.6%-46.1%$166.88MN/A48.9290Positive NewsDERMJourney Medical2.2827 of 5 stars$7.13-3.8%$9.50+33.2%+27.4%$166.71M$56.13M-18.3590Positive NewsKYTXKyverna Therapeutics2.6839 of 5 stars$3.83-13.0%$18.50+383.0%-61.2%$165.75M$7.03M-1.1396Positive NewsACRSAclaris Therapeutics2.2205 of 5 stars$1.53-3.5%$8.71+471.4%+20.5%$165.13M$18.72M-1.10100BIOABioAge LabsN/A$4.49-3.0%N/AN/A$160.97MN/A0.00N/AIPHAInnate Pharma2.6427 of 5 stars$1.76+3.2%$11.00+526.8%-18.0%$160.39M$21.77M0.00220News Coverage Related Companies and Tools Related Companies Cybin Competitors Rapt Therapeutics Competitors Tiziana Life Sciences Competitors Alpha Cognition Competitors Black Diamond Therapeutics Competitors Journey Medical Competitors Kyverna Therapeutics Competitors Aclaris Therapeutics Competitors BioAge Labs Competitors Innate Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MURA Stock Alerts